Bushra Salman: Avatrombopag Shows Promise in Heavily Pretreated Chronic ITP
Bushra Salman, Pharmacist at Sultan Qaboos University, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in Frontiers in Medicine, adding:
“I am delighted to share our latest publication in Frontiers in Medicine:
‘Avatrombopag in Heavily Pretreated Chronic Immune Thrombocytopenia: A Single-Center Experience from Oman.’
Patients with chronic immune thrombocytopenia (ITP) who have failed multiple prior therapies remain challenging to treat.
In our real-world case series from Oman, avatrombopag demonstrated clinically meaningful benefits beyond improving platelet counts.
Key findings include:
- 75 percent of patients achieved platelet counts greater than or equal to 50 × 10⁹/L.
- 60 percent of patients with high baseline platelet transfusion requirements experienced a reduction in platelet transfusion burden.
- 83.3 percent achieved a steroid-sparing effect, with 66.7 percent becoming completely steroid-free during follow-up.
These findings highlight the potential of avatrombopag not only to improve platelet responses but also outcomes that can significantly improve patient care and quality of life.”
Title: Avatrombopag in heavily pretreated chronic immune thrombocytopenia: a single center experience from Oman
Authors: Nashwa Al-Sharji, Bushra Salman, Shireen Al-Zadjali, Mohammed Al-Huneini
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 20, 2026, 13:29Factor XI Deficiency and the Challenge of Unpredictable Bleeding – EHC
-
Sep 20, 2026, 13:18Cindy Howry: FDA Approves First Treatment for Ataxia-Telangiectasia
-
Sep 20, 2026, 13:08Mohammad Salar Amoli: When Routine Coagulation Tests Miss von Willebrand Disease
-
Sep 20, 2026, 12:55Stelios Andreadis։ Human Salivary Gland Organoids Offer New Potential for Regenerative Medicine
-
Sep 20, 2026, 12:43Obi Light Ogbonnia: The Power of Lived Experience in Sickle Cell Care
-
Sep 20, 2026, 12:34Sabrine Mekni: Advancing HSCT for Children With Fanconi Anemia
-
Sep 20, 2026, 12:11Giacomo Buso: Silent Atherosclerosis Begins Earlier Than Expected
-
Sep 20, 2026, 12:0310 Posts Not to Miss This Week
-
Sep 20, 2026, 11:27Edward Lee Carter: Prasugrel Dosing Matters in P2Y12 Inhibitor Comparisons After PCI